Global PD-L1 and PIK3CA Testing Market Report, History and Forecast 2017-2028, Breakdown Data by Companies, Key Regions, Types and Application

PD-L1 Biomarker Testing measures the amount of PDL1 on cancer cells. PDL1 is a protein that helps keep immune cells from attacking nonharmful cells in the body. Normally, the immune system fights foreign substances like viruses and bacteria, and not your own healthy cells. Some cancer cells have high amounts of PDL1. This allows the cancer cells to "trick" the immune system, and avoid being attacked as foreign, harmful substances.
Current PD-L1 testing is based on immunohistochemistry (IHC) methods. Immunohistochemistry (IHC) is the process whereby antibodies are used to detect proteins (antigens) in cells within a tissue section (for instance liver, pancreas or the heart).

PD-L1 is a ligand that binds to PD-1 (programmed cell death-1), expressed on activated T cells, to evade anti-tumor responses. PD-L1 plays a role in inhibiting T cell activation and proliferation and has emerged as an important target in cancer treatment. PD-L1 protein detection by immunohistochemistry (IHC) testing is widely used as a predictive biomarker assay for anti–PD-1/PD-L1 therapies.

PIK3CA is a gene that encodes a lipid kinase involved in multiple signaling pathways. These pathways influence cellular functions such as growth, death, and proliferation. PIK3CA mutations activate the PI3K-PTEN-AKT pathway, which is downstream from both the EGFR and the RAS-RAF-MAPK pathways. PIK3CA mutations may cause oncogenic transformation independent of RAS or RAF mutations.

PIK3CA mutations occur in about 15% to 30% of breast, endometrial, and colon cancers. They occur less frequently in lung cancer and other types of cancer. Presence of PIK3CA mutations is associated with poor prognosis and lack of response to specific therapies in patients with breast, endometrial, or colon cancer.

Market Insights

The research report studies the PD-L1 and PIK3CA Testing market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.

Due to the COVID-19 pandemic, the global PD-L1 and PIK3CA Testing market size is estimated to be worth US$ 521.8 million in 2021 and is forecast to a readjusted size of US$ 1964.3 million by 2028 with a CAGR of 20.6% during the forecast period 2022-2028.

The classification of PD-L1 and PIK3CA Testing Product includes PD-L1 Testing and PIK3CA Testing. PD-L1 accounted for a share of 80% in the global PD-L1 and PIK3CA Testing Product market.

PD-L1 and PIK3CA Testing Product is widely used in Hospital, Diagnostic Center and Other. In PD-L1 and PIK3CA Testing Product market, the Diagnostic Center holds an important share in terms of Application.

North America is the largest consumption place, with a market share nearly 57% . Following North America, Europe is the second largest consumption place with the market share of 28%.

Market competition is intense. Agilent Technologies, Roche, QIAGEN, Amoy Diagnostics, ACCB Biotech, etc. The top five vendors held 84% of the market share.

Segment Scope

An intensive study of key type and application segments has been done in this segmentation section. The authors of the report have provided reliable figures including revenue forecast data by type and application for the period 2017-2028. They have also studied how the segments are gaining or losing growth in various geographies and their respective countries. Thanks to this study, readers can thoroughly grasp the growth pattern and potential of different segments.

Segment by Type

PD-L1 Testing

PIK3CA Testing

Segment by Application

Hospital

Diagnostic Center

Others

Regional Scope

This segment of the report offers a thorough regional study of the global PD-L1 and PIK3CA Testing market. Drivers and restraints for each region are broadly examined in the report. Readers will get familiar with the driving forces and challenges that are specific to the regions. The specialists have identified growth opportunities in key geographical regions and their respective countries to aid players to reinforce their presence. All the regions and their countries in the report are assessed based on the growth rate and revenue according to the consumption for the period 2017-2028. This geographical analysis will help readers to gain in-depth knowledge of the regional growth. The key geographical regions surveyed in this research report involve North America, Europe, Asia Pacific, Central and South America, and Middle East and Africa. The report has specifically covered major countries including United States, Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, China Taiwan, Indonesia, Thailand, Malaysia, Mexico, Brazil, Turkey, Saudi Arabia, UAE, etc.

Key Players

This section has provided an exhaustive analysis of the strategies that the companies are focusing on to stay ahead of other players. The strategies mainly involve research and development, new product developments, and mergers and acquisitions. The researchers have also provided revenue shares of the key companies, company overview, and the latest company developments so as to help players to sustain the cutthroat competition. In this section, the report offers global revenue data of manufacturers for the period 2017-2022. Following is the list of key manufacturers observed in this research study:

Agilent Technologies

Roche

QIAGEN

EntroGen

Amoy Diagnostics

ACCB Biotech

Frequently Asked Questions

Which application segment captured the leading share in the PD-L1 and PIK3CA Testing market?

How fragmented is the PD-L1 and PIK3CA Testing market?

Which are the key growth drivers in the PD-L1 and PIK3CA Testing market?

Which are the top strategies undertaken by the PD-L1 and PIK3CA Testing market players?

Which technological trends are likely to affect the PD-L1 and PIK3CA Testing market?

What is the expected PD-L1 and PIK3CA Testing market size by 2028?

Which companies are dominating the PD-L1 and PIK3CA Testing market?

Which region is projected to witness the fastest growth in the future?

What factors are restraining the PD-L1 and PIK3CA Testing market growth?

Which are the emerging companies in the PD-L1 and PIK3CA Testing market?